Zachary VanGundy
Immunology and Microbiology · The Ohio State University
Publications
24
Citations
483
Est. group size
—
Recurring co-author estimate
Active years
14
Publishing since 2011
Zachary VanGundy's work spans immunology, cancer biology, and transplant medicine, with studies on genetic markers (such as ANRIL, CYP3A5, PARP1, and POLD2) that may predict outcomes after stem cell transplantation, as well as research on immune tolerance and experimental treatments for autoimmune disease and cancer cell lines. Overall, the research explores how genetic variation and immune regulation affect transplant success, cancer progression, and disease treatment strategies.
Publication output has been sparse and irregular over the last decade, with occasional active years (such as 2019) interspersed with multiple years of no recorded output, and a low recent average of 0.4 publications per year.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation
Frontiers in Pharmacology · 2024
- <i>PARP1</i> and <i>POLD2</i> as prognostic biomarkers for multiple myeloma in autologous stem cell transplant
Haematologica · 2023
- Association of<i>ANRIL</i>Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation
Anticancer Research · 2020
- Treatment of Experimental Autoimmune Encephalomyelitis by Codelivery of Disease Associated Peptide and Dexamethasone in Acetalated Dextran Microparticles
Figshare · 2020
- PTC209, a Specific Inhibitor of BMI1, Promotes Cell Cycle Arrest and Apoptosis in Cervical Cancer Cell Lines
Anticancer Research · 2019
- Cisplatin Induced the Expression of<i>SEI1</i>(<i>TRIP-Br1</i>) Oncogene in Human Oral Squamous Cancer Cell Lines
Anticancer Research · 2019
- Polymorphism in <i>ANRIL</i> is associated with relapse in patients with multiple myeloma after autologous stem cell transplant
Molecular Carcinogenesis · 2017
- Physiologic Doses of Bilirubin Contribute to Tolerance of Islet Transplants by Suppressing the Innate Immune Response
Cell Transplantation · 2016
- Anticancer Research×3
- Molecular Carcinogenesis×1
- Cell Transplantation×1
- Haematologica×1
- Frontiers in Pharmacology×1
- Haoxin Zhao
Immunology and Microbiology · The Ohio State University
- Yan Wang
Immunology and Microbiology · The Ohio State University
- Vandana Anang
Immunology and Microbiology · The Ohio State University
- Anthony Cannon
Immunology and Microbiology · Indiana University
- Carter Allen
Immunology and Microbiology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile